Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as ge...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

SunnySD Oct. 25 at 3:58 PM

$CGTX

0 · Reply

aerts2js Oct. 25 at 12:05 AM

$CGTX did this company forget they have a PR department? It’s been nearly 2 months. Prior to Sept 3rd they were releasing PR statements every week or two - going back years. What is going on?

1 · Reply

Biopharma75 Oct. 24 at 5:17 PM

$CGTX done buying today locked all my cgtx long . both my cgtx and dvlt will be big winner of 2025 and 2026 .

0 · Reply

HappyStockholder Oct. 24 at 3:53 PM

$CGTX OMG!!!! THE SKY IS FALLING!!!!CHICKEN LITTLE. FINANCIAL TERRORISTS!!!! 🤡🤡🤡🤡🤡🤡😂😂😂😂😂😂 ONE OF THE LEAST SHORTED STOCKS ON THE MARKET

2 · Reply

ERPBlast Oct. 24 at 2:34 PM

$CGTX Short Interest Ratio: 6.12 Days to Cover I wana see 10+ days

0 · Reply

Dmsrz8 Oct. 24 at 11:39 AM

$CGTX well, maybe we can gain a few back today. Hopefully next week Lisa provides some type of updates, guidance, or insight. Looking forward to the end of the year and what this company can continue to advance

0 · Reply

mdunbar Oct. 23 at 8:46 PM

$CGTX I think most investors are on the hold mode waiting for tomorrow’s cpi numbers. If we don’t get a surprise reading tomorrow, it will be clear skies for a few weeks.

1 · Reply

Rjcamel2355 Oct. 23 at 7:22 PM

$CGTX Big volume buy spike randomly.

1 · Reply

Silvercaine Oct. 23 at 7:09 PM

$CGTX Nice news for bio investors.https://www.fda.gov/news-events/press-announcements/fda-publishes-filing-checklists-prevent-submission-delays

1 · Reply

Lovemypicks Oct. 23 at 6:30 PM

$CGTX rico case material

0 · Reply

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 7 weeks ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

Aug 27, 2025, 8:53 PM EDT - 2 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

Aug 26, 2025, 4:00 PM EDT - 2 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 26, 2025, 10:08 AM EDT - 2 months ago

Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating

Aug 12, 2025, 4:00 PM EDT - 2 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

Jul 29, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 4 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 4 months ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 5 months ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 5 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 7 months ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 1:15 PM EDT - 7 months ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 8 months ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 12, 2025, 4:05 PM EDT - 8 months ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 8 months ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 9 months ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 10 months ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 11:06 AM EST - 11 months ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 7:22 AM EST - 11 months ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 11 months ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 11 months ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 29, 2024, 12:55 PM EDT - 1 year ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Aug 22, 2024, 7:31 AM EDT - 1 year ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 11, 2024, 12:55 AM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Jul 29, 2024, 7:14 AM EDT - 1 year ago

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

Jul 26, 2024, 4:11 PM EDT - 1 year ago

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

May 21, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

May 7, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

SunnySD Oct. 25 at 3:58 PM

$CGTX

0 · Reply

aerts2js Oct. 25 at 12:05 AM

$CGTX did this company forget they have a PR department? It’s been nearly 2 months. Prior to Sept 3rd they were releasing PR statements every week or two - going back years. What is going on?

1 · Reply

Biopharma75 Oct. 24 at 5:17 PM

$CGTX done buying today locked all my cgtx long . both my cgtx and dvlt will be big winner of 2025 and 2026 .

0 · Reply

HappyStockholder Oct. 24 at 3:53 PM

$CGTX OMG!!!! THE SKY IS FALLING!!!!CHICKEN LITTLE. FINANCIAL TERRORISTS!!!! 🤡🤡🤡🤡🤡🤡😂😂😂😂😂😂 ONE OF THE LEAST SHORTED STOCKS ON THE MARKET

2 · Reply

ERPBlast Oct. 24 at 2:34 PM

$CGTX Short Interest Ratio: 6.12 Days to Cover I wana see 10+ days

0 · Reply

Dmsrz8 Oct. 24 at 11:39 AM

0 · Reply

mdunbar Oct. 23 at 8:46 PM

$CGTX I think most investors are on the hold mode waiting for tomorrow’s cpi numbers. If we don’t get a surprise reading tomorrow, it will be clear skies for a few weeks.

1 · Reply

Rjcamel2355 Oct. 23 at 7:22 PM

$CGTX Big volume buy spike randomly.

1 · Reply

Silvercaine Oct. 23 at 7:09 PM

$CGTX Nice news for bio investors.https://www.fda.gov/news-events/press-announcements/fda-publishes-filing-checklists-prevent-submission-delays

1 · Reply

Lovemypicks Oct. 23 at 6:30 PM

$CGTX rico case material

0 · Reply

BillionerOfKing Oct. 23 at 6:23 PM

$CGTX Current Stock Price: $1.66 No options data available.

0 · Reply

Aimforsuccess Oct. 23 at 5:53 PM

$CGTX Financial terrorists still making their presence known?

0 · Reply

mdunbar Oct. 23 at 4:40 PM

$CGTX This is a make-or-break territory. Bulls need to defend 1.65 level for the rebound scenario to stay alive. If we close below 1.6 that would confirm the short-term uptrend is broken.

0 · Reply

Zerocool510 Oct. 23 at 2:47 PM

$CGTX looks like Lilly will be selling this Q1 2026. Should help us out when we officially go to market with Shimmer an Shine treatment. https://finance.yahoo.com/news/offering-first-fda-cleared-alzheimer-131512914.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAImrBEna6wqhaPBMU_SEu2UI66otc-iVRtNfyuLqSkfsyroMKX-XXfWZlvbI9fIFYSxrvUxFITYSOTDW4VY2Kc65UAIPrUUO6qqMBVgRNCJUCCn6YG5ji8rkmLA4qzbh2dCF0BGK5G2wfAF2llJ7crFrONj53LA4p3eLq74BLmgZ

0 · Reply

IzErbDyIn Oct. 23 at 2:02 PM

$CGTX squints 4 ever

0 · Reply

Silvercaine Oct. 23 at 1:10 PM

$CGTX Shorts have returned 1.6mil shares within the past 24 hours🤔

1 · Reply

Rjcamel2355 Oct. 23 at 1:05 PM

$CGTX Just a matter of time.

0 · Reply

makingdoughfromoptions Oct. 23 at 11:23 AM

$CGTX The two P3 ALZ studies will run well over $100 million, possibly closer to $200MM. If they pan out well you can expect a SP many times today's pittance. BUT, you can also expect further dilution. Easily by 50%. Expect it and weigh against the massive market and profits for their ALZ treatment.

1 · Reply

Dmsrz8 Oct. 23 at 11:15 AM

$CGTX

0 · Reply

Silvercaine Oct. 23 at 5:36 AM

$CGTX Rome044 blocked me for pointing out that borrowing his 100k shares for shorts is unethinical play against your position. People get touchy when you don't agree with everything in the their investment approach.Whatever sport...

0 · Reply

BarryLong28 Oct. 23 at 3:12 AM

$CGTX

0 · Reply

ROMEO44 Oct. 22 at 8:20 PM

$CGTX Mm mostly trading back and forth loading up on the sheep

0 · Reply

Market Cap	124.99M
Revenue (ttm)	0.00
Net Income (ttm)	-33.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,045,900
Avg Vol	4,755,296
Day's Range	N/A - N/A
Shares Out	73.52M
Stochastic %K	34%
Beta	1.19
Analysts	Strong Sell
Price Target	$3.25